Implanet SA (ALIMP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Implanet SA (ALIMP) has a cash flow conversion efficiency ratio of -0.700x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-283.00K ≈ $-330.86K USD) by net assets (€404.00K ≈ $472.32K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Implanet SA to measure how many days the company can operate on defensive assets alone.
Implanet SA - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Implanet SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Implanet SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Implanet SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aquaron Acquisition Corp. Common Stock
NASDAQ:AQU
|
-0.032x |
|
Seoam Machinery Industry Co.Ltd
KQ:100660
|
-0.021x |
|
Pico (Thailand) Public Company Limited
BK:PICO
|
-0.070x |
|
Perusahaan Sadur Timah Malaysia Perstima Bhd
KLSE:5436
|
0.069x |
|
Orient Precision Industries Inc
KQ:065500
|
-0.015x |
|
Micro Digital Co. Ltd
KQ:305090
|
0.133x |
|
WOOJUNG BIO Inc
KQ:215380
|
-0.033x |
|
Aware Inc
NASDAQ:AWRE
|
-0.117x |
Annual Cash Flow Conversion Efficiency for Implanet SA (2012–2025)
The table below shows the annual cash flow conversion efficiency of Implanet SA from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Implanet SA market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €404.00K ≈ $472.32K |
€-589.00K ≈ $-688.60K |
-1.458x | +54.39% |
| 2024-12-31 | €727.00K ≈ $849.94K |
€-2.32 Million ≈ $-2.72 Million |
-3.197x | -138.44% |
| 2023-12-31 | €-174.00K ≈ $-203.42K |
€-1.45 Million ≈ $-1.69 Million |
8.316x | +1324.93% |
| 2022-12-31 | €3.54 Million ≈ $4.14 Million |
€-2.40 Million ≈ $-2.81 Million |
-0.679x | +45.84% |
| 2021-12-31 | €2.80 Million ≈ $3.28 Million |
€-3.52 Million ≈ $-4.11 Million |
-1.254x | +58.26% |
| 2020-12-31 | €1.02 Million ≈ $1.19 Million |
€-3.07 Million ≈ $-3.59 Million |
-3.003x | -53.51% |
| 2019-12-31 | €1.44 Million ≈ $1.68 Million |
€-2.81 Million ≈ $-3.28 Million |
-1.956x | -5.80% |
| 2018-12-31 | €2.40 Million ≈ $2.81 Million |
€-4.44 Million ≈ $-5.19 Million |
-1.849x | -160.38% |
| 2017-12-31 | €6.29 Million ≈ $7.35 Million |
€-4.46 Million ≈ $-5.22 Million |
-0.710x | -16.42% |
| 2016-12-31 | €9.66 Million ≈ $11.29 Million |
€-5.89 Million ≈ $-6.89 Million |
-0.610x | +12.91% |
| 2015-12-31 | €9.73 Million ≈ $11.37 Million |
€-6.81 Million ≈ $-7.96 Million |
-0.700x | +4.55% |
| 2014-12-31 | €7.21 Million ≈ $8.43 Million |
€-5.29 Million ≈ $-6.19 Million |
-0.734x | -88.93% |
| 2013-12-31 | €13.87 Million ≈ $16.21 Million |
€-5.39 Million ≈ $-6.30 Million |
-0.388x | +54.44% |
| 2012-12-31 | €4.68 Million ≈ $5.47 Million |
€-3.99 Million ≈ $-4.66 Million |
-0.852x | -- |
About Implanet SA
Implanet S.A., together with its subsidiaries, manufactures and sells implants and medical instruments for orthopedic surgery in France, the United States, Europe, the Middle East, Africa, and internationally. The company offers spinal and knee products, including Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Olea, Saxxo, Swingo, Shark, Origin, and Jazz Frame, as well as ISS-… Read more